cefpodoxime (vantin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cefpodoxime is an orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class. Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Cefpodoxime is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions: acute otitis media; pharyngitis and/or tonsillitis; community-acquired pneumonia; acute bacterial exacerbation of chronic bronchitis; gonorrhea; uncomplicated skin and skin structure infections; acute maxillary sinusitis and uncomplicated urinary tract infections (cystitis). Common adverse reactions include diarrhea, nausea, vaginal fungal infections, vulvovaginal infections, abdominal pain, headache. Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.   NCATS

Chemistry

  • SMILES: COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\C3=CSC(N)=N3)C2=O)C(O)=O
  • InChIKey: WYUSVOMTXWRGEK-HBWVYFAYSA-N
  • Mol. Mass: 427.455
  • ALogP: 0.83
  • ChEMBL Molecules:
    cefpodoxime proxetil  
    cefpodoxime  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$2.8610 - $4.2069
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-(isopropoxycarbonyloxy)ethyl-7-(2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetamido)-3-methoxymethyl-8-oxo-5-thia-1-azabicyclo(4,2,0)-oct-2-ene-2-carboxylate | 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(methoxymethyl)-8-oxo-, monosodium salt, (6r-(6alpha,7beta(z)))- | banan | cefodox | cefoprox | cefpodoxima | cefpodoxime | cefpodoxime acid | cefpodoxime proxetil | cefpodoximum | cephalosporin 807 | cephpodoxime proxetil | cepodem | cs 807 | cs-807 | doxef | orelox | orelox paed | r 3746 | r-3746 | r 3763 | r-3763 | ru 51746 | ru-51746 | u 76252 | u-76252 | u-76,252 | u 76253a | u-76,253a | vantin

Organizations (20)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (9)


 

Bronchitis, Chronic (approved 2007)

Community-Acquired Infections (approved 2007)

Cystitis (approved 2007)

Gonorrhea (approved 2007)

Maxillary Sinusitis (approved 2007)

Otitis Media (approved 2006)

Pharyngitis (approved 2007)

Staphylococcal Skin Infections (approved 2007)

Tonsillitis (approved 2007)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Arthritis, Rheumatoid (Phase 1/Phase 2)

Bone Diseases, Infectious (Phase 4)

Diarrhea (Phase 1)

Healthy Volunteers (Phase 1)

Infections (Phase 4)

Intestinal Neoplasms (Phase 4)

Neoplasms (Phase 1)

Osteoarthritis (Phase 1/Phase 2)

Sinusitis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue